{"nctId":"NCT04459338","briefTitle":"A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion","startDateStruct":{"date":"2021-03-04","type":"ACTUAL"},"conditions":["Healthy"],"count":11,"armGroups":[{"label":"Saline, Then Exendin-9,39","type":"EXPERIMENTAL","interventionNames":["Biological: Exendin-9,39","Other: Saline"]},{"label":"Exendin-9,39, Then Saline","type":"EXPERIMENTAL","interventionNames":["Biological: Exendin-9,39","Other: Saline"]}],"interventions":[{"name":"Exendin-9,39","otherNames":[]},{"name":"Saline","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 20 weight-stable, non-diabetic subjects\n\nExclusion Criteria:\n\n* Age \\< 25 or \\> 65 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).\n* HbA1c â‰¥5.9%\n* Use of glucose-lowering agents.\n* For female subjects: positive pregnancy test at the time of enrollment or study\n* History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.\n* Active systemic illness or malignancy.\n* Symptomatic macrovascular or microvascular disease.","healthyVolunteers":true,"sex":"ALL","minimumAge":"25 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Insulin Secretion Rate During Exendin-9,39 Infusion vs. Insulin Secretion Rate During Saline Infusion","description":"This is the area under the curve for insulin secretion over the duration of the hyperglycemic clamp (0 to 300 minutes during the study in the Clinical Research Unit).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"191","spread":"23"},{"groupId":"OG001","value":"171","spread":"19"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":11},"commonTop":["Infusion line lost","Nausea"]}}}